Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor–induced lethal hepatitis
Montserrat Marí, … , Carmen García-Ruiz, José C. Fernández-Checa
Montserrat Marí, … , Carmen García-Ruiz, José C. Fernández-Checa
Published March 15, 2004
Citation Information: J Clin Invest. 2004;113(6):895-904. https://doi.org/10.1172/JCI19852.
View: Text | PDF
Category: Article

Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor–induced lethal hepatitis

  • Text
  • PDF
Abstract

S-adenosyl-L-methionine (SAM) is synthesized by methionine adenosyltransferases (MATs). Ablation of the liver-specific MAT1A gene results in liver neoplasia and sensitivity to oxidant injury. Here we show that acidic sphingomyelinase (ASMase) mediates the downregulation of MAT1A by TNF-α. The levels of MAT1A mRNA as well as MAT I/III protein decreased in cultured rat hepatocytes by in situ generation of ceramide from exogenous human placenta ASMase. Hepatocytes lacking the ASMase gene (ASMase–/–) were insensitive to TNF-α but were responsive to exogenous ASMase-induced downregulation of MAT1A. In an in vivo model of lethal hepatitis by TNF-α, depletion of SAM preceded activation of caspases 8 and 3, massive liver damage, and death of the mice. In contrast, minimal hepatic SAM depletion, caspase activation, and liver damage were seen in ASMase–/– mice. Moreover, therapeutic treatment with SAM abrogated caspase activation and liver injury, thus rescuing ASMase+/+ mice from TNF-α–induced lethality. Thus, we have demonstrated a new role for ASMase in TNF-α–induced liver failure through downregulation of MAT1A, and maintenance of SAM may be useful in the treatment of acute and chronic liver diseases.

Authors

Montserrat Marí, Anna Colell, Albert Morales, Covadonga Pañeda, Isabel Varela-Nieto, Carmen García-Ruiz, José C. Fernández-Checa

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
SAM therapy in fulminant hepatitis. Experimental ASMase+/+ mice (n = 40)...
SAM therapy in fulminant hepatitis. Experimental ASMase+/+ mice (n = 40) were treated with Gal/LPS; control mice (Saline, in B; n = 40) were treated with saline. Mice were divided in three groups: one group received SAM (5 mg/mouse intraperitoneally) or saline every hour for 8 hours after treatment with Gal/LPS; in addition, half of the mice receiving SAM therapy were pretreated with BSO (4 mmol/kg). (A) Serum ALT or AST levels. *P < 0.05 versus Gal/LPS; #P < 0.05 versus ASMase+/+ mice treated with Gal/LPS + SAM. AST, aspartate aminotransferase. (B) Hematoxylin and eosin staining of livers with or without SAM administration or BSO treatment. Scale bars: 5 μm. (C) Hepatocellular SAM levels of ASMase+/+ mice challenged with Gal/LPS with or without SAM therapy. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (D) Caspase activity in livers from ASMase+/+ mice with or without SAM treatment. *P < 0.05 versus untreated mice; #P < 0.05 versus Gal/LPS group. (E) Hepatic GSH levels in ASMase+/+ mice with or without SAM treatment. *P < 0.05 versus values at time 0; #P < 0.05 versus Gal/LPS group. (F) Serum TNF-α levels in ASMase+/+ mice at various time points after Gal/LPS treatment with or without SAM therapy.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts